AU2005229015C1 - Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin - Google Patents

Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin Download PDF

Info

Publication number
AU2005229015C1
AU2005229015C1 AU2005229015A AU2005229015A AU2005229015C1 AU 2005229015 C1 AU2005229015 C1 AU 2005229015C1 AU 2005229015 A AU2005229015 A AU 2005229015A AU 2005229015 A AU2005229015 A AU 2005229015A AU 2005229015 C1 AU2005229015 C1 AU 2005229015C1
Authority
AU
Australia
Prior art keywords
antibody
integrin
alkyl
aryl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005229015A
Other languages
English (en)
Other versions
AU2005229015B2 (en
AU2005229015A1 (en
Inventor
Amha Atakilit
Dean Sheppard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of AU2005229015A1 publication Critical patent/AU2005229015A1/en
Priority to AU2012216372A priority Critical patent/AU2012216372B2/en
Publication of AU2005229015B2 publication Critical patent/AU2005229015B2/en
Application granted granted Critical
Publication of AU2005229015C1 publication Critical patent/AU2005229015C1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2005229015A 2004-04-02 2005-03-30 Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin Ceased AU2005229015C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012216372A AU2012216372B2 (en) 2004-04-02 2012-08-22 Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55917504P 2004-04-02 2004-04-02
US60/559,175 2004-04-02
PCT/US2005/011222 WO2005094391A2 (en) 2004-04-02 2005-03-30 METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASE ASSOCIATED WITH αVβ5 INTEGRIN

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012216372A Division AU2012216372B2 (en) 2004-04-02 2012-08-22 Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin

Publications (3)

Publication Number Publication Date
AU2005229015A1 AU2005229015A1 (en) 2005-10-13
AU2005229015B2 AU2005229015B2 (en) 2012-08-30
AU2005229015C1 true AU2005229015C1 (en) 2013-01-17

Family

ID=35064346

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005229015A Ceased AU2005229015C1 (en) 2004-04-02 2005-03-30 Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin

Country Status (14)

Country Link
US (2) US20050226865A1 (https=)
EP (2) EP2394662B1 (https=)
JP (2) JP5223072B2 (https=)
CN (1) CN1964740A (https=)
AU (1) AU2005229015C1 (https=)
CA (1) CA2562038C (https=)
CY (1) CY1114497T1 (https=)
DK (1) DK1734996T3 (https=)
ES (2) ES2671522T3 (https=)
HR (1) HRP20130782T1 (https=)
PL (1) PL1734996T3 (https=)
PT (1) PT1734996E (https=)
RS (1) RS52918B (https=)
WO (1) WO2005094391A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2767409C (en) * 2009-07-24 2018-10-30 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with .alpha.v.beta.5 integrin
WO2013181666A2 (en) * 2012-06-01 2013-12-05 Isis Pharmaceuticals, Inc. Antisense compounds targeting genes associated with fibronectin
WO2014144616A2 (en) * 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 5 antibodies and uses thereof
HK1219740A1 (zh) * 2013-03-15 2017-04-13 Biogen Ma Inc. 使用抗αVβ5抗体治疗和预防急性肾损伤
US10005838B2 (en) * 2013-07-19 2018-06-26 The Regents Of The University Of California Milk fat globule epidermal growth factor 8 regulates fatty acid uptake
MA40536A (fr) * 2014-09-12 2016-03-17 Biogen Ma Inc Anticorps anti-alpha v bêta 5 humanisés et leurs utilisations
US11339221B2 (en) 2017-11-01 2022-05-24 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014192A1 (en) * 1996-10-02 1998-04-09 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO1998030542A1 (en) * 1997-01-08 1998-07-16 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO2002012501A2 (en) * 2000-08-07 2002-02-14 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
WO2004020435A1 (en) * 2002-08-16 2004-03-11 Janssen Pharmaceutica N.V. Piperidinyl compounds that selectively bind integrins

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US72500A (en) * 1867-12-24 Improvement in bleaceisg and scouring hemp, flax, aid other fibres
US19037A (en) * 1858-01-05 Washing-machine
US19206A (en) * 1858-01-26 Hydrant
US37889A (en) * 1863-03-10 Mode of
US171271A (en) * 1875-12-21 Improvement in bob-sleds
US139398A (en) * 1873-05-27 Improvement in lamp-extinguishers
US181440A (en) * 1876-08-22 Improvement in steam-boiler furnaces
US77321A (en) * 1868-04-28 Amos bank
US10023A (en) * 1853-09-20 Machine fob sawing sticks eob broom-handles
US18192A (en) * 1857-09-15 And samuel m
US19035A (en) * 1858-01-05 mallary
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5231114A (en) 1990-06-22 1993-07-27 Wakunaga Seiyaku Kabushiki Kaisha Polysulfides compounds and lipid peroxidation inhibitor containing the polysulfide compounds as active ingredient
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5527679A (en) 1991-05-01 1996-06-18 Dana Farber Cancer Institute β5 protein and DNA encoding the same
DE4123341A1 (de) 1991-07-15 1993-01-21 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4142366A1 (de) * 1991-07-15 1993-06-24 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US6291196B1 (en) * 1992-01-31 2001-09-18 Research Corporation Technologies, Inc. Melanoma and prostate cancer specific antibodies for immunodetection and immunotherapy
CA2131389A1 (en) 1992-03-02 1993-09-16 John M. Maraganore Thrombin receptor antagonists
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5780426A (en) 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
HUP9802675A3 (en) * 1995-08-14 2000-09-28 Scripps Research Inst Methods and compositions useful for inhibition of alfa-v beta-5 mediated angiogenesis
US7053041B1 (en) * 1996-05-31 2006-05-30 The Scripps Research Institute Methods and compositions useful for inhibition of αvβ5mediated angiogenesis
EP0915698A4 (en) 1996-05-01 1999-08-11 Lilly Co Eli TREATMENT PROCEDURE FOR VEGF-RELATED DISEASES
NZ513800A (en) 1996-08-12 2001-09-28 Welfide Corp Treatment of diseases using Rho kinase inhibitors
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
EE04752B1 (et) * 1997-08-08 2006-12-15 The Regents Of The University Of California Monoklonaalne antikeha, seda tootev hübridoom ja antikeha kasutamine
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
JP2002531466A (ja) 1998-12-01 2002-09-24 プロテイン デザイン ラブス， インコーポレイテッド γ−インターフェロンに対するヒト化抗体
EP1140205A2 (en) 1998-12-30 2001-10-10 Edema Clearance, Inc. GENE THERAPY FOR PULMONARY EDEMA USING ADENOVIRUS VECTORS ENCODING Na,K-ATPase
EP2314700A1 (en) 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US6399581B1 (en) 1999-05-11 2002-06-04 Harbor Branch Oceanographic Institution, Inc. Compound possessing potent thrombin receptor antagonist activity
CA2352957A1 (en) 1999-09-29 2001-04-05 Ortho-Mcneil Pharmaceutical, Inc. Isonipecotamides for the treatment of integrin-mediated disorders
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6544982B1 (en) 1999-10-29 2003-04-08 Merck & Co., Inc. Thrombin receptor antagonists
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
CA2397194C (en) 2000-01-20 2011-05-17 Mark E. Duggan Alpha v integrin receptor antagonists
EP1254116A4 (en) 2000-01-24 2003-04-23 Merck & Co Inc ALPHA V INTEGRIN RECEPTOR ANTAGONISTS
US6403612B2 (en) 2000-01-31 2002-06-11 Merck & Co., Inc. Thrombin receptor antagonists
US6515023B2 (en) 2000-01-31 2003-02-04 Merck & Co., Inc. Thrombin receptor antagonists
WO2001056607A1 (en) 2000-02-03 2001-08-09 Eisai Co., Ltd. Integrin expression inhibitors
US6518244B2 (en) 2000-03-09 2003-02-11 Intimax Corporation Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof
US6970452B2 (en) 2000-03-13 2005-11-29 Curitell Communications Inc. Common subscriber managing apparatus and method based on functional modeling of a common subscriber server for use in an ALL-IP network and method therefor
AU2001259078A1 (en) 2000-04-18 2001-10-30 Edema Clearance, Inc. Gene theraphy for pulmonary edema using adenovirus vectors encoding a beta2adrenergic receptor gene
UY26780A1 (es) 2000-06-15 2002-01-31 Pharmacia Corp Cicloalquil avb3 antagonistas
DE10041423A1 (de) 2000-08-23 2002-03-07 Merck Patent Gmbh Biphenylderivate
US20020072500A1 (en) 2000-09-27 2002-06-13 Thomas Rogers Hydroxy acid integrin antagonists
JP2004513953A (ja) 2000-10-24 2004-05-13 メルク　エンド　カムパニー　インコーポレーテッド ジベンズオキサゼピンαＶインテグリン受容体アンタゴニスト
JP2004532616A (ja) 2000-12-28 2004-10-28 ジョンソン・アンド・ジョンソン・リサーチ・ピー・ティー・ワイ・リミテッド 二本鎖ｒｎａ仲介遺伝子抑制
EP1393075A4 (en) 2001-04-04 2006-06-14 Allergan Inc METHODS OF SCREENING AND USE OF ANGIOGENESIS INHIBITORS
DE60208186T2 (de) 2001-04-09 2006-08-24 Ortho-Mcneil Pharmaceutical Research Inc. Chinazolin- und chinazolinähnliche verbindungen zur behandlung von integrin-vermittelten erkrankungen
US20040019206A1 (en) 2001-09-27 2004-01-29 Peter Ruminiski Lactone integrin antagonists
WO2004105757A2 (en) 2003-05-29 2004-12-09 Schering Aktiengesellschaft Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
JO3421B1 (ar) 2011-06-20 2019-10-20 H Lundbeck As طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014192A1 (en) * 1996-10-02 1998-04-09 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO1998030542A1 (en) * 1997-01-08 1998-07-16 Smithkline Beecham Corporation Vitronectin receptor antagonists
US6069158A (en) * 1997-01-08 2000-05-30 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO2002012501A2 (en) * 2000-08-07 2002-02-14 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
WO2004020435A1 (en) * 2002-08-16 2004-03-11 Janssen Pharmaceutica N.V. Piperidinyl compounds that selectively bind integrins

Also Published As

Publication number Publication date
RS52918B (sr) 2014-02-28
WO2005094391A3 (en) 2005-12-01
CY1114497T1 (el) 2016-10-05
US7815908B2 (en) 2010-10-19
DK1734996T3 (da) 2013-06-10
EP1734996A2 (en) 2006-12-27
CN1964740A (zh) 2007-05-16
JP2013028611A (ja) 2013-02-07
AU2005229015B2 (en) 2012-08-30
JP5223072B2 (ja) 2013-06-26
WO2005094391A2 (en) 2005-10-13
HK1098077A1 (en) 2007-07-13
EP1734996B1 (en) 2013-05-22
EP2394662A3 (en) 2012-02-22
EP1734996A4 (en) 2008-09-10
US20090280118A1 (en) 2009-11-12
EP2394662A2 (en) 2011-12-14
HRP20130782T1 (en) 2013-09-30
CA2562038C (en) 2017-04-25
US20050226865A1 (en) 2005-10-13
JP2007531733A (ja) 2007-11-08
AU2005229015A1 (en) 2005-10-13
CA2562038A1 (en) 2005-10-13
JP5681149B2 (ja) 2015-03-04
ES2671522T3 (es) 2018-06-06
PT1734996E (pt) 2013-07-18
ES2411965T3 (es) 2013-07-09
EP2394662B1 (en) 2018-03-21
PL1734996T3 (pl) 2013-09-30

Similar Documents

Publication Publication Date Title
US7815908B2 (en) Methods and compositions for treating and preventing disease associated with αVβ5 integrin
EP1149111B1 (en) Method and composition for angiogenesis inhibition
WO2010030813A2 (en) Methods for inhibiting ocular angiogenesis
WO2013032948A1 (en) Method for inhibiting cellular activation by insulin-like growth factor-1
US20230181750A1 (en) Mask peptides and masked anti-ptk7 antibodies comprising such
US10087252B2 (en) Methods and compositions for treating and preventing disease associated with αvβ5 integrin
AU2012216372B2 (en) Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
KR20190113398A (ko) 항-Tspan12 항체 또는 그의 항원-결합 단편, 및 그의 용도
US20050281821A1 (en) Method and composition for angiogenesis inhibition
HK1098077B (en) Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin
ME02086B (me) Postupci i smeše za lečenje i prevenciju bolesti koje su povezane sa alfa v beta 5 integrinom
NZ621515B2 (en) Method for inhibiting cellular activation by insulin-like growth factor-1

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 06 SEP 2012 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 06 SEP

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired